| Drug ID: | Drug197 |
|---|---|
| Drug Name: | Etelcalcetide |
| CID: | 71511839 |
| DrugBank ID: | DB12865 |
| Modality: | Small Molecule |
| Groups: | NULL |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT03633708, , NCT03969329, , NCT03960437, , NCT03795558, , NCT03299244, , NCT03283098, , NCT01785849, , NCT01788046, , NCT01896232, , NCT02833857, , NCT01785875, , NCT01932970, , NCT01134562, , NCT02102204, , NCT01134549, , NCT01576146, , NCT01254565, , NCT01414114 |
| Molecular Formula: | C38H73N21O10S2 |
| Molecular Weight: | 1048.3 g/mol |
| Isomeric SMILES: | C[C@H](C(=O)N[C@H](CCCN=C(N)N)C(=O)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](C)NC(=O)[C@@H](CSSC[C@@H](C(=O)O)N)NC(=O)C |
| Synonyms: | etelcalcetide; Velcalcetide; 1262780-97-1; AMG-416; KAI-4169; Telcalcetide; Etelcalcetida; AMG 416; UNII-60ME133FJB; 60ME133FJB |
| Phase 0: | 0 |
| Phase 1: | 5 |
| Phase 2: | 6 |
| Phase 3: | 9 |
| Phase 4: | 0 |
| Description: | NULL |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt1385 | 71511839 | Etelcalcetide | 846 | CASR | Homo sapiens (human) | None | |
| dt1386 | 71511839 | Etelcalcetide | 846 | CASR | Homo sapiens (human) | 23674604 | Calcium sensing receptor agonist |
| dt1387 | 71511839 | Etelcalcetide | 846 | CASR | Homo sapiens (human) | 24235081 | Agonist |
| dt1388 | 71511839 | Etelcalcetide | 846 | CASR | Homo sapiens (human) | 23674604 | Positive |
| dt1389 | 71511839 | Etelcalcetide | 846 | CASR | Homo sapiens (human) | Modulator | |
| dt1390 | 71511839 | Etelcalcetide | None | -- | Severe acute respiratory syndrome coronavirus 2 | 37943932 | None |
| dt1391 | 71511839 | Etelcalcetide | 54 | ACP5 | Homo sapiens (human) | Modulator | |
| dt1392 | 71511839 | Etelcalcetide | 846 | CASR | Homo sapiens (human) | Agonist |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| No data available | |||||||
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S07 | Blockade of cytokine | Cytokine signalling | apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab | Various T-cell subsets, their differentiation pathways and … | Details |
No related literature
You can run management commands to establish drug-literature associations